

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA **复星医药**

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2024 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the 2024 third quarterly report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) (the “**2024 Third Quarterly Report**”) for the three months ended 30 September 2024 (the “**Reporting Period**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and is unaudited.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

29 October 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Pan Donghui and Mr. Chen Yuqing; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *For identification purposes only*

I. IMPORTANT NOTICE

The board of directors (the “**Board**”) and the supervisory committee (the “**Supervisory Committee**”) of the Company and its directors, supervisors and senior management warrant that the quarterly report does not contain any false information, misleading statements or material omission and severally and jointly accept legal responsibility for the truthfulness, accuracy and completeness of the contents contained herein.

Mr. Wu Yifang, the person in charge of the Company, Mr. Chen Zhanyu, Chief Financial Officer and Ms. Yan Jia, the Director of the Accounting Department (Accounting Officer) warrant the truthfulness, accuracy and completeness of the financial information contained in the quarterly report.

The financial statements for the third quarter of 2024 of the Group are unaudited.

I. MAJOR FINANCIAL INFORMATION OF THE GROUP

(I) Major accounting information and financial indicators

Unit: Yuan Currency: RMB

Item	The Reporting Period	Increase or decrease in the Reporting Period compared with the corresponding period of last year (%)	From the beginning of the year to the end of the Reporting Period	Increase or decrease from the beginning of the year to the end of the Reporting Period over the corresponding period of last year (%)
Operating revenue	10,449,076,271.75	12.30	30,911,889,002.90	0.69
Net profit attributable to shareholders of the listed company	785,843,766.10	55.43 ^{Note 1}	2,010,642,360.52	-11.93
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss	582,174,869.86	474.77 ^{Note 1}	1,836,246,177.02	24.58
Net cash flow generated from operating activities	1,079,633,457.17	65.68 ^{Note 2}	2,986,637,355.17	21.33 ^{Note 2}
Basic earnings per share (RMB/share)	0.29	52.63 ^{Note 1}	0.75	-12.79
Diluted earnings per share (RMB/share)	0.29	52.63 ^{Note 1}	0.75	-11.76
Return on weighted average net asset (%)	1.66	Increase by 0.55 percentage point	4.32	Decrease by 0.73 percentage point

	At the end of the Reporting Period	At the end of last year	Increase or decrease at the end of the Reporting Period compared with the end of last year (%)
Total assets	115,264,761,757.14	113,469,604,813.45	1.58
Equity attributable to shareholders of the listed company	47,301,473,095.24	45,684,761,548.05	3.54

Note: The “Reporting Period” refers to the three months period from the beginning of this quarter to the end of this quarter, the same below.

Note 1: During the Reporting Period (July-September), the Group realized net profit attributable to shareholders of the listed company of RMB786 million and net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss of RMB582 million, and period-on-period changes of which were mainly due to the combined effect of (1) the disposal of COVID-19 related products and assets with indications of impairment, and the accrual of provision for the impairment of related assets in the same period of 2023; and (2) the period-on-period decrease in share of investment income of associates and joint ventures during the Reporting Period.

Note 2: During the Reporting Period (July-September) and from the beginning of the year to the end of the Reporting Period (January-September), the Group recorded period-on-period increase in net cash flow generated from operating activities, which was mainly due to changes in operating profit and contribution by improvement of supply chain management and operation efficiency.

Extraordinary gain or loss items and amounts

Unit: Yuan Currency: RMB

Extraordinary gain or loss items	Amount of the period	Amount from the beginning of the year to the end of the Reporting Period
Gain or loss on disposal of non-current assets, including the part written off for provision for impairment on assets	20,258,060.14	223,052,241.71
Government grants included in profit or loss for the current period, excluding government grants closely related to the Company's normal operation, in line with national policies, entitled in accordance with the determined standards, and having a continuous impact on the Company's profit or loss	35,449,667.19	103,999,911.91
Gain or loss arising from changes in fair value of financial assets and financial liabilities held by non-financial enterprises and gain or loss arising from disposal of financial assets and financial liabilities, except effective hedging business related to the Company's normal operations	142,230,117.47	-177,184,101.23
Non-operating income and expenses other than those stated above	-37,936,934.11	-36,022,932.42
Less: Effect of income tax	-1,177,648.90	11,621,276.21
Impact on non-controlling interests (after tax)	-42,490,336.64	-72,172,339.73
Total	203,668,896.24	174,396,183.50

For extraordinary gain or loss items not stated in the “Explanatory Announcement No. 1 on Information Disclosure by Public Issuers of Securities — Extraordinary Gain or Loss” that are recognized as extraordinary gain or loss items and with a material amount, and extraordinary gain or loss items stated in the “Explanatory Announcement No. 1 on Information Disclosure by Public Issuers of Securities — Extraordinary Gain or Loss” that are defined as recurring gain or loss items, the Company shall provide the reasons.

Not applicable

(II) Changes in the principal accounting information and financial indicators and reasons for the changes

Currency: RMB

Name of item	Ratio of change (%)	Main reason
Net profit attributable to shareholders of the listed company for the Reporting Period	55.43	
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss for the Reporting Period	474.77	Please refer to the Note 1 of “Major accounting information and financial indicators” above
Basic earnings per share for the Reporting Period (RMB/share)	52.63	
Diluted earnings per share for the Reporting Period (RMB/share)	52.63	
Net cash flow generated from operating activities for the Reporting Period	65.68	

II. SHAREHOLDER INFORMATION

(I) Total number of holders of ordinary shares and the number of holders of preference shares with resumed voting rights, and the shareholding status of the Top 10 shareholders

Unit: Share

Total number of holders of ordinary shares as at the end of the Reporting Period	262,536	Total number of holders of preference shares with resumed voting rights as at the end of the Reporting Period (if any)	N/A			
The shareholding status of the Top 10 shareholders (excluding shares lent through refinancing)						
Name of shareholders	Capacity	Shareholding	Percentage of shareholding (%)	Number of restricted shares held	Shares pledged, marked or locked up	
					Status	Number
Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司)	Domestic nonstate owned legal entity	889,890,955 ^{Note 1}	33.30	0	Pledged	577,900,000
HKSCC NOMINEES LIMITED ^{Note 2}	Unknown	551,372,815	20.63	0	Unknown	0
Hong Kong Securities Clearing Company Limited ^{Note 3}	Others	59,963,220	2.24	0	None	0
China Securities Finance Corporation Limited* (中國證券金融股份有限公司)	Others	38,736,079	1.45	0	None	0
Industrial and Commercial Bank of China — Huatai Bairui CSI 300 Trading Open-ended Index Securities Investment Fund* (中國工商銀行股份有限公司—華泰柏瑞滬深300交易型開放式指數證券投資基金)	Securities investment fund	23,810,925	0.89	0	None	0
Bank of China Limited — China Merchants National Securities Biomedical Index Classified Securities Investment Fund* (中國銀行股份有限公司—招商國證生物醫藥指數分級證券投資基金)	Securities investment fund	23,195,318	0.87	0	None	0
China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Trading Open-ended Index Securities Investment Fund* (中國建設銀行股份有限公司—易方達滬深300醫藥衛生交易型開放式指數證券投資基金)	Securities investment fund	19,886,125	0.74	0	None	0
National Social Security Fund Portfolio 113* (全國社保基金一一三組合)	Others	16,842,340	0.63	0	None	0
China Construction Bank Corporation — E Fund CSI 300 Trading Open-ended Index Initiated Securities Investment Fund* (中國建設銀行股份有限公司—易方達滬深300交易型開放式指數發起式證券投資基金)	Securities investment fund	16,137,498	0.60	0	None	0
Basic Pension Insurance Fund Portfolio 802* (基本養老保險基金八零二組合)	Others	12,541,395	0.47	0	None	0

The shareholding status of the Top 10 unrestricted shareholders (excluding shares lent through refinancing)			
Name of shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司)	889,890,955 ^{Note 1}	RMB ordinary shares	889,890,955
HKSCC NOMINEES LIMITED ^{Note 2}	551,372,815	Overseas listed foreign shares	551,372,815
Hong Kong Securities Clearing Company Limited ^{Note 3}	59,963,220	RMB ordinary shares	59,963,220
China Securities Finance Corporation Limited* (中國證券金融股份有限公司)	38,736,079	RMB ordinary shares	38,736,079
Industrial and Commercial Bank of China — Huatai Bairui CSI 300 Trading Open-ended Index Securities Investment Fund* (中國工商銀行股份有限公司—華泰柏瑞滬深300交易型開放式指數證券投資基金)	23,810,925	RMB ordinary shares	23,810,925
Bank of China Limited — China Merchants National Securities Biomedical Index Classified Securities Investment Fund* (中國銀行股份有限公司—招商國證生物醫藥指數分級證券投資基金)	23,195,318	RMB ordinary shares	23,195,318
China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Trading Open-ended Index Securities Investment Fund* (中國建設銀行股份有限公司—易方達滬深300醫藥衛生交易型開放式指數證券投資基金)	19,886,125	RMB ordinary shares	19,886,125
National Social Security Fund Portfolio 113* (全國社保基金一一三組合)	16,842,340	RMB ordinary shares	16,842,340
China Construction Bank Corporation — E Fund CSI 300 Trading Open-ended Index Initiated Securities Investment Fund* (中國建設銀行股份有限公司—易方達滬深300交易型開放式指數發起式證券投資基金)	16,137,498	RMB ordinary shares	16,137,498
Basic Pension Insurance Fund Portfolio 802* (基本養老保險基金八零二組合)	12,541,395	RMB ordinary shares	12,541,395
Description of the related relationship or concerted action of the above shareholders	As at the end of the Reporting Period, except for holding 889,890,955 A shares of the Company, Fosun High Tech, the controlling shareholder, and its controlling shareholder, Fosun International Limited, held 71,533,500 and 6,000,000 H shares of the Company through HKSCC NOMINEES LIMITED, respectively. Save as disclosed above, the Company does not know whether any related relationship or concerted action exists between any of other abovementioned shareholders of tradable shares.		
Description of Top 10 shareholders and Top 10 unrestricted shareholders participating in securities margin trading and refinancing business (if any)	Top 10 shareholders and Top 10 unrestricted shareholders held shares through ordinary securities accounts. Please refer to the table below for details of their involvement in the refinancing business.		

Note 1: Representing A shares only. As at the end of the Reporting Period, Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司) (“**Fosun High Tech**”), the controlling shareholder, held an aggregate of 961,424,455 shares of the Company (including 889,890,955 A shares and 71,533,500 H shares), representing approximately 35.98% of the total shares of the Company (i.e., 2,672,398,711 shares; the same hereinafter) as at the end of the Reporting Period.

Note 2: HKSCC NOMINEES LIMITED, i.e. Hong Kong Securities Clearing Company Nominees Limited, is holding shares on behalf of multiple clients (shares held by it at the end of the Reporting Period include an aggregate of 77,533,500 H shares of the Company held by Fosun High Tech, the controlling shareholder of the Company, and its controlling shareholder, Fosun International Limited, through it, representing approximately 2.90% of the total share of the Company as at the end of the Reporting Period).

Note 3: Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB ordinary shares under Shanghai-Hong Kong Stock Connect.

Shareholders holding more than 5% of the shares, the Top 10 shareholders and the Top 10 shareholders with unrestricted tradable shares involved in the shares lent through refinancing business

Unit: Share

Shareholders holding more than 5% of the shares, the Top 10 shareholders and the Top 10 shareholders with unrestricted tradable shares involved in the shares lent through refinancing business								
Name of shareholders (Full name)	Shareholding of ordinary and credit accounts at the beginning of the period ^{Note}		The shares lent through refinancing but not yet returned at the beginning of the period ^{Note}		Shareholding of ordinary and credit accounts at the end of the period		The shares lent through refinancing but not yet returned at the end of the period	
	Total number	Percentage (%)	Total number	Percentage (%)	Total number	Percentage (%)	Total number	Percentage (%)
Industrial and Commercial Bank of China Limited — Huatai Bairui CSI 300 Trading Open-ended Index Securities Investment Fund* (中國工商銀行股份有限公司—華泰柏瑞滬深300交易型開放式指數證券投資基金)	9,369,625	0.35	57,600	0.002	23,810,925	0.89	0	0.00
China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Trading Open-ended Index Securities Investment Fund* (中國建設銀行股份有限公司—易方達滬深300醫藥衛生交易型開放式指數證券投資基金)	18,389,093	0.69	778,800	0.03	19,886,125	0.74	0	0.00
China Construction Bank Corporation — E Fund CSI 300 Trading Open-ended Index Initiated Securities Investment Fund* (中國建設銀行股份有限公司—易方達滬深300交易型開放式指數發起式證券投資基金)	3,006,853	0.11	587,500	0.02	16,137,498	0.60	0	0.00

Note: Refers to 1 January 2024

Changes in the Top 10 shareholders and the Top 10 shareholders with unrestricted tradable shares due to shares lent/returned through refinancing business

Not Applicable

III. OTHER REMINDER

The investors are reminded to pay attention to other significant information concerning the Company's operations during the Reporting Period

(I) Overview of operating results

In the first three quarters of 2024, the operating revenue of the Group amounted to RMB30.912 billion, representing a year-on-year increase of 0.69% and, excluding COVID-related products, approximately 5.74%, net profit attributable to shareholders of the listed company amounted to RMB2.011 billion (in particular, net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss amounted to RMB1.836 billion, representing a year-on-year increase of 24.58%).

The Group further focused on innovative drugs and high-value devices, and continued to promote lean operations, cost reduction, efficiency improvement, and asset lightweighting to optimize its asset and financial structure. It actively facilitated the improvement in supply chain management and operational efficiency, achieving a healthy operating cash flow. In the first three quarters of 2024, net cash flow from operating activities was approximately RMB2.987 billion, representing a year-on-year increase of 21.33%. The administrative expenses rate recorded a year-on-year decrease of 0.15 percentage point, and excluding the effect of newly merged and acquired enterprises, administrative expenses on the same basis decreased by approximately RMB0.3 billion.

Since July 2024, the Group's main R&D and operations progress are as follows:

1. *Continued to promote the innovation transformation and the development and launch of innovative products*

In terms of innovative R&D, the Group continued to focus on pipelines with advantages, optimized management and resources allocation of R&D projects and ensured the priority of promoting key projects, thereby realizing efficient commercialization of projects' results and continuous launch of innovative products. In the first three quarters of 2024, the total R&D expenditure of the Group amounted to RMB3.915 billion. In particular, the R&D expenses amounted to RMB2.648 billion. In addition to the investment in self-owned R&D, the Group fully implemented the open R&D model by incubating and making investment in the R&D projects through measures, including among others, initiating and setting up/managing industry funds, in order to ensure the sustainability of innovative R&D of drugs.

The updates on the Group's major R&D pipelines during the Reporting Period are set out below:

Progress during the Reporting Period	Drug name/code	Drug category	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch	Remarks	
Approved for launch	Trastuzumab injection (trade name in Canada: Adheroza)	Biological product	For the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer (Canada)							—
	Type A Botulinum toxin for injection (trademark in Chinese mainland: DAXXIFY [®])	Therapeutic biological product	Temporary improvement on moderate to severe glabellar lines caused by corrugator supercilii and/or procerus muscle activity in adults							—
NDA accepted	SBK010 oral solution	Chemical drug	For the treatment of mild to moderate acute ischemic stroke							—
Met the primary study endpoint of phase III clinical study	HLX11 (recombinant anti-HER2 domain II humanized monoclonal antibody injection)	Therapeutic biological product	For the neoadjuvant therapy of HER2-positive, HR-negative early or locally advanced breast cancer (international multi-center)							—
Under phase II clinical study	HLX53 (anti-TIGIT Fc fusion protein)	Therapeutic biological product	First-line treatment of locally advanced or metastatic hepatocellular carcinoma (HCC)						In combination with Han Si Zhuang (serplulimab injection) and Han Bei Tai (bevacizumab injection)	
IND approved	Serplulimab injection	Biological product	First-line treatment for metastatic colorectal cancer (mCRC) (Japan)						In combination with bevacizumab and chemotherapy, <i>Note 1</i>	
	FH-2001capsule	Chemical drug	For the treatment of advanced solid tumor						In combination with serplulimab injection	
	23-valent pneumococcal polysaccharide vaccine	Preventive biological product	Prevention of pneumococcal diseases						<i>Note 2</i>	
	Rabies vaccine for human use (freeze dried) (human diploid cells)	Preventive biological product	Prevention of Rabies prophylaxis						<i>Note 3</i>	
	XS-04	Chemical drug	For the treatment of hematological malignancies						—	
	HLX17 (recombinant anti-PD-1 humanised monoclonal antibody injection)	Therapeutic biological product	For the treatment of melanoma, non-small cell lung cancer, esophageal cancer, head and neck squamous cell carcinoma, colorectal cancer, hepatocellular carcinoma, triple-negative breast cancer, and tumors with microsatellite instability or mismatch repair deficiency						—	

Note 1: In July 2024, the Phase III of international multi-center study of serplulimab injection (PD-1 inhibitor), independently developed by the Group, in combination with bevacizumab and chemotherapy for the first-line treatment of patients with metastatic colorectal cancer (mCRC) obtained the approval from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.

Note 2: In July 2024, the application for Phase I and Phase III clinical trials of the Group's self-developed 23-valent pneumococcal polysaccharide vaccine was approved by the National Medical Products Administration ("NMPA") for the prevention of pneumococcal diseases caused by infections with the relevant pneumococcal strains.

Note 3: In September 2024, the application for Phase I and Phase III clinical trials of the Group's self-developed rabies vaccine (human diploid cells) for human use (freeze dried) was approved by the NMPA for the prevention of rabies.

Meanwhile, during the Reporting Period, several products and pipeline clinical trial results of the Group were presented at industry conferences or published in journals:

The interim analysis results of the Phase III study of Foritinib (SAF-189s), a self-developed innovative drug of the Group for the treatment of ALK-positive non-small cell lung cancer (NSCLC), were released at the 2024 World Conference on Lung Cancer (WCLC). The above-mentioned study showed that Foritinib demonstrated good overall efficacy, significantly improving PFS compared to crizotinib, while reducing the risk of CNS progression. Its safety profile was manageable, with no new safety signals observed after treatment. Foritinib is expected to address current clinical challenges in the treatment of ALK-positive NSCLC, offering a new treatment option for NSCLC patients.

The results of the Phase III multi-center, double-blind, placebo-controlled clinical trial in China for the Group's licensed-in A botulinum toxin for injection (trade name in Chinese mainland: DAXXIFY[®]), used for the treatment of moderate to severe glabellar lines, were published in Journal of Plastic, Reconstructive & Aesthetic Surgery (JPRAS). The study showed that the product provides long-lasting efficacy and good safety in treating moderate to severe glabellar lines in Chinese subjects.

The results of the Phase II clinical study (HLX22-GC-201) on HLX22, an innovative anti-HER2 monoclonal antibody of the Group, in combination with Hanquyou (trastuzumab injection) and chemotherapy for first-line treatment of HER2-positive advanced or metastatic gastric/gastroesophageal junction (G/GEJ) cancer were successively presented at the 2024 European Society of Medical Oncology Gastrointestinal Cancer Congress (ESMO GI) and published in MED, a flagship medical journal of Cell Press. Results from conducted study showed that adding HLX22 to the combination of HLX02 (trastuzumab injection) and chemotherapy can improve the first-line treatment outcomes for patients with HER2-positive G/GEJ cancer, with manageable safety.

The real-world data from a multi-center study on serplulimab, self-developed by the Group, in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) were presented at the 2024 World Conference on Lung Cancer (WCLC). These real-world data validated the findings from the clinical trial study and offered strong evidence to support the use of serplulimab in combination with etoposide and platinum drugs for the first-line treatment for ES-SCLC. In addition, during the Reporting Period, the serplulimab injection also received a favourable opinion from the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA), being recommended for the approval of it in combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). The CHMP’s opinion will be submitted to the European Commission (EC) as a reference for marketing authorization application.

2. Increased Shareholding in Fosun Kite (a cell therapy platform) to 100%

On 13 September 2024, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.* (上海復星醫藥產業發展有限公司) (“**Fosun Pharmaceutical Industrial**”), a subsidiary of the Company, jointly entered into the Equity Transfer Agreement with Kite Pharma Inc. and Fosun Kite Biotechnology Co., Ltd. (“**Fosun Kite**”, which is now renamed as Shanghai Fosun Kairos Biotechnology Co., Ltd.* (復星凱瑞(上海)生物科技股份有限公司)). Fosun Kite and Kite Pharma Inc. also made a comprehensive amendment and restatement in respect of the relevant license agreement entered into in 2017 and reached the Amended and Restated License Agreement. Pursuant to the agreement, Fosun Pharmaceutical Industrial will hold an additional 50% equity interest of Fosun Kite (upon the completion of the equity transfer, Fosun Pharmaceutical Industrial will hold 100% of equity interest of Fosun Kite, and Fosun Kite will be included in the Group’s consolidated financial statements), and Fosun Kite will also continue to advance the development and commercialisation cooperation of the existing licensed product Axi-Cel (namely, Fosun Kite’s launched product “Yi Kai Da”) and Brexu-Cel (Fosun Kite’s projects in progress FKC889) with Kite Pharma Inc. in Chinese mainland, Hong Kong and Macau.

(II) Others

1. *Progress of A Share Repurchase*

At the 47th meeting of the ninth session of the Board of the Company on 26 March 2024, the A share repurchase plan was considered and approved, and it was agreed that the Company could repurchase the A shares of the Company with its own funds through centralized price bidding on the trading system of Shanghai Stock Exchange. The total repurchase fund shall be not less than RMB100 million and not more than RMB200 million and the repurchase price shall be not more than RMB30 per share (inclusive). The repurchase period is 6 months from the date of consideration and approval of the A share repurchase plan by the Board. As a result of the Profit Distribution 2023, the A share repurchase price limit was adjusted to RMB29.7302 per share (inclusive) with effect from 6 August 2024 (being the ex-dividend date of the A Shares for the Profit Distribution 2023) pursuant to the A share repurchase plan.

As of the close of trading on 25 September 2024, the implementation period of the A share repurchase plan expired and the Company completed the plan. Under the A share repurchase plan, the Company actually repurchased 5,677,700 A Shares (representing approximately 0.21% of the total number of shares of the Company <i.e., 2,672,398,711 Shares> as at 25 September 2024) at a total repurchase price of approximately RMB126.64 million (excluding transaction costs).

2. *Progress of H Share Repurchase*

Pursuant to the general mandate to repurchase H shares of the Company, which was considered and approved at the 2023 annual general meeting, the 2024 First A Shareholders Class Meeting and the 2024 First H Shareholders Class Meeting (the “**General Meetings**”) respectively, the H share repurchase plan was considered and approved at the 55th meeting of the ninth session of the Board and it was agreed that the Company could repurchase the H shares of the Company with its own funds up to and including 31 December 2024. The number of H shares to be repurchased shall not exceed 5% (i.e. not more than 27,597,025 shares) of the total number of H shares (i.e. 551,940,500 shares) of the Company as at the date of the resolution of the General Meetings (i.e. 26 June 2024).

Pursuant to the H share repurchase plan, the Company repurchased H shares for the first time on 28 August 2024. As of the end of the Reporting Period, the Company had in aggregate repurchased 5,471,500 H shares (representing approximately 0.20% of the total number of shares of the Company <i.e., 2,672,398,711 Shares> as of the end of the Reporting Period). The total repurchase price was approximately HK\$66.90 million (excluding transaction costs).

3. Progress of Increase in Shareholding by a Controlling Shareholder

Fosun High Tech, a controlling shareholder of the Company, planned to further increase its shareholding in the Company (including A Shares and/or H Shares) by way of, including but not limited to, centralised price bidding or block trade at the stock exchanges and transfer by agreement (and/or through parties acting in concert with it) within the 12-month period commencing from 13 September 2023 (inclusive), if and where appropriate, and the cumulative total consideration thereof shall not be less than RMB100 million (including the total consideration for an increase in shareholding of A Shares of not less than RMB100 million) and the additional shareholding interest to be acquired in aggregate shall not exceed 2% of the total number of shares of the Company as at 13 September 2023 (i.e. 2,672,156,611 Shares, the same below) (and the aggregated number of shares in the Company to be acquired in the 12-month period on a rolling basis shall not exceed 2% of the total issued shares of the Company). Fosun High Tech and/or parties acting in concert with it shall not reduce its/their shareholding in the Company during the implementation of the shareholding increase plan and within the statutory restricted period.

As of 12 September 2024, the term of the shareholding increase plan expired. Under the shareholding increase plan, Fosun High Tech acquired a total of 4,295,000 A Shares of the Company, representing approximately 0.16% of the total number of shares of the Company as at 13 September 2023, with a cumulative consideration of approximately RMB101.19 million.

4. Merger by Absorption and Privatization of Shanghai Henlius

By resolutions of the Board of the Company dated 24 June 2024 and 23 August 2024 respectively, the privatization proposal of Shanghai Henlius Biotech, Inc. (“**Shanghai Henlius**”, a subsidiary of the Company), and the amendments thereto were approved. Pursuant to the proposal (as amended), Shanghai Fosun New Medicine Research Co., Ltd.* (上海復星新藥研究股份有限公司) (“**Fosun New Medicine**”, a subsidiary of the Company) (as the offeror and acquirer) proposed to acquire and cancel all shares of Shanghai Henlius (including H shares and unlisted shares) held by other existing shareholders of Shanghai Henlius by cash and/or share alternative (the “**Merger**”), and to privatize Shanghai Henlius. Upon the completion of the Merger, Fosun New Medicine (as the subsisting entity after the Merger) will inherit and assume all assets, liabilities, interests, businesses, personnel, contracts and all rights and obligations of Shanghai Henlius, and the legal entity of Shanghai Henlius will be eventually deregistered.

As of the end of the Reporting Period, the transaction is still under review by the relevant competent authorities and subject to the approval of the general meeting and the H shareholders class meeting of Shanghai Henlius. The voluntary delisting application of Shanghai Henlius is also subject to the approval of The Stock Exchange of Hong Kong Limited. There are material uncertainties regarding the Merger and the voluntary delisting of Shanghai Henlius.

5. *Repurchase and Cancellation of Certain Restricted A Shares under the 2022 Restricted A Share Incentive Scheme*

Pursuant to the 2022 Restricted A Share Incentive Scheme and the relevant authorizations considered and approved at the 2022 second extraordinary general meeting, the 2022 second A Shareholders class meeting and the 2022 second H Shareholders class meeting of the Company, respectively, the circumstances of repurchase and cancellation as stipulated in the Restricted A Share Incentive Plan occurred due to (1) the resignation or attainment of the retirement age stipulated by the law and the Company of certain participants of the first grant and the reserved grant; and (2) the Group level performance appraisal for 2023 not being met. On 7 August 2024, the Board and the Supervisor Committee approved the repurchase and cancellation of an aggregate of 1,072,246 Restricted A Share by the Company at a total repurchase amount of RMB22,830,809.73; at the same time, it was agreed that the cash dividends for the relevant years in relation to such proposed repurchased and cancelled shares, which were originally held in escrow by the Company, would be forfeited by the Company. The repurchase of the aforesaid 1,072,246 Restricted A Shares was completed on 27 September 2024 and the cancellation was completed on 8 October 2024. Upon completion of the cancellation of these shares, the total number of shares of the Company was reduced from 2,672,398,711 shares to 2,671,326,465 shares and the registered capital was reduced from RMB2,672,398,711 to RMB2,671,326,465.

6. *Forfeiture of Certain Units not yet Vested under the 2022 H Share Employee Share Ownership Scheme*

Pursuant to the 2022 H Share Employee Share Ownership Scheme and the relevant authorizations considered and approved at the 2022 second extraordinary general meeting of the Company, the Board approved the forfeiture of an aggregate of 22,963,400 H Share Employee Share Ownership Scheme units not yet vested by the management committee of the H Share Employee Share Ownership Scheme on 7 August 2024 due to (1) the resignation or attainment of the retirement age stipulated by the law and the Company of certain participants of the first grant and the reserved grant; and (2) the Group level performance appraisal for 2023 not being met.

IV. QUARTERLY FINANCIAL STATEMENTS

(I) Audited report

Not applicable

(II) Financial statements

Consolidated Balance Sheet

30 September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2024	31 December 2023
Current assets:		
Cash and bank balances	13,507,968,050.27	13,693,590,965.39
Financial assets held for trading	2,122,081,327.17	1,888,496,433.69
Bills receivable	39,863,241.76	24,492,488.40
Trade receivable	8,415,900,587.49	7,643,736,270.74
Receivables financing	581,006,972.93	642,568,580.95
Prepayments	967,836,158.08	884,582,172.88
Other receivables	701,701,033.55	626,657,270.84
Including: Interests receivable	—	—
Dividends receivable	8,852,336.97	14,750,826.36
Inventories	7,435,227,104.84	7,537,767,765.75
Contract assets	81,715,178.48	145,887,291.75
Assets held for sale	71,975,680.09	—
Other current assets	602,024,017.39	704,789,708.23
Total current assets	34,527,299,352.05	33,792,568,948.62
Non-current assets:		
Long-term receivables	89,088,743.05	85,322,818.08
Long-term equity investments	24,945,672,701.77	23,919,398,947.82
Other equity instrument investments	13,693,570.56	52,774,220.89
Other non-current financial assets	929,663,864.01	1,040,114,413.33
Fixed assets	14,923,836,331.96	15,129,371,156.29
Construction in progress	4,666,715,968.67	4,938,281,247.38
Right-of-use assets	2,270,781,259.43	2,171,744,487.74
Intangible assets	13,031,835,137.26	13,482,016,130.59
Development expenditures	4,895,929,231.72	3,896,108,184.77
Goodwill	10,800,669,199.00	10,851,999,207.39
Long-term deferred expenditures	1,053,960,382.25	778,805,942.86
Deferred tax assets	791,144,883.76	624,470,612.53
Other non-current assets	2,324,471,131.65	2,706,628,495.16
Total non-current assets	80,737,462,405.09	79,677,035,864.83
Total assets	115,264,761,757.14	113,469,604,813.45

Consolidated Balance Sheet (Continued)

30 September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2024	31 December 2023
Current liabilities:		
Short-term loans	18,679,639,582.44	14,728,454,129.15
Bills payable	816,474,047.07	652,252,423.59
Trade payable	5,525,583,103.27	5,507,366,277.73
Contract liabilities	1,007,116,288.38	1,200,496,066.44
Wages payable	1,682,723,247.65	1,978,115,885.93
Tax payable	537,016,754.88	536,965,065.37
Other payables	4,140,748,898.28	4,202,172,433.33
Including: Interests payable	—	—
Dividends payable	46,955,296.32	17,316,885.59
Non-current liabilities due within one year	5,005,300,788.55	4,826,597,231.71
Other current liabilities	122,979,383.85	125,164,024.57
Total current liabilities	37,517,582,094.37	33,757,583,537.82
Non-current liabilities:		
Long-term loans	8,630,183,539.06	13,504,923,111.26
Bonds payable	240,000,000.00	—
Lease liabilities	2,217,236,916.94	2,049,589,366.84
Long-term payables	615,863,880.74	507,764,019.67
Long-term wages payable	174,091,466.87	141,475,527.30
Deferred income	605,077,498.44	639,398,945.80
Deferred tax liabilities	3,464,986,579.56	3,445,190,578.09
Other non-current liabilities	2,605,135,611.53	2,807,419,290.39
Total non-current liabilities	18,552,575,493.14	23,095,760,839.35
Total liabilities	56,070,157,587.51	56,853,344,377.17
Owners' Equity (or shareholders' equity):		
Share capital	2,671,326,465.00	2,672,398,711.00
Capital reserve	17,524,643,878.68	16,853,454,175.22
Less: Treasury shares	206,895,300.74	41,928,227.94
Other comprehensive income	-1,473,923,714.20	-1,300,090,249.71
Surplus reserve	2,958,415,025.58	2,958,415,919.58
Unappropriated profit	25,827,906,740.92	24,542,511,219.90
Total equity attributable to the owners (or shareholders) of the parent company	47,301,473,095.24	45,684,761,548.05
Non-controlling interests	11,893,131,074.39	10,931,498,888.23
Total owners' equity (or shareholders' equity)	59,194,604,169.63	56,616,260,436.28
Total liabilities and owners' equity (or shareholders' equity)	115,264,761,757.14	113,469,604,813.45

*Person in charge
of the Company:*
Wu Yifang

Chief Financial Officer:
Chen Zhanyu

*Director of
the Accounting Department:*
Yan Jia

Consolidated Income Statement
January — September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2024 (Jan-Sep)	First three quarters of 2023 (Jan-Sep)
I. Total operating revenue	30,911,889,002.90	30,700,119,056.12
Including: Operating revenue	30,911,889,002.90	30,700,119,056.12
II. Total operating costs	29,362,812,762.85	30,284,279,170.47
Including: Operating costs	15,889,599,601.50	15,779,521,220.28
Tax and surcharges	233,828,884.22	197,962,111.28
Selling and distribution expenses	6,592,219,720.43	7,226,681,929.85
General and administrative expenses	3,144,563,560.08	3,168,933,375.04
Research and development expenses	2,648,036,346.49	3,155,101,729.15
Finance expenses	854,564,650.13	756,078,804.87
Including: Interest expenses	1,067,876,593.66	947,670,221.32
Interest income	279,711,179.34	265,614,789.02
Plus: Other gains	258,894,140.64	303,789,784.16
Investment income (“-” indicating loss)	1,498,762,805.90	2,182,417,314.63
Including: Investment income from associates and joint ventures	1,214,652,267.53	1,495,922,362.55
Gains from changes in fair value (“-” indicating loss)	-106,245,847.25	806,336,386.57
Credit impairment losses (“-” indicating loss)	-54,465,502.75	-81,582,526.65
Asset impairment losses (“-” indicating loss)	-40,946,606.35	-290,902,742.88
Gains from disposal of assets (“-” indicating loss)	2,513,587.58	6,299,669.38
III. Operating profit (“-” indicating loss)	3,107,588,817.82	3,342,197,770.86
Plus: Non-operating revenue	34,567,912.80	49,590,722.66
Less: Non-operating expenses	70,590,845.22	99,332,003.91
IV. Total profit (“-” indicating total loss)	3,071,565,885.40	3,292,456,489.61
Less: Income tax expenses	553,048,247.94	638,646,952.94
V. Net profit (“-” indicating net loss)	2,518,517,637.46	2,653,809,536.67
(I) Classification according to the continuity of operation		
1. Net profit from continuing operation (“-” indicating net loss)	2,518,517,637.46	2,653,809,536.67
2. Net profit from discontinued operation (“-” indicating net loss)	—	—
(II) Classification according to ownership		
1. Net profit attributable to the owners of the parent company (“-” indicating net loss)	2,010,642,360.52	2,283,065,930.63
2. Profit or loss attributable to non-controlling interests (“-” indicating net loss)	507,875,276.94	370,743,606.04

Consolidated Income Statement (Continued)
January — September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2024	First three quarters of 2023
VI. Other comprehensive income, net of tax	-213,927,299.31	383,047,217.57
(I) Other comprehensive income attributable to the owners of the parent company, net of tax	-177,247,663.14	219,204,955.15
1. Other comprehensive income not reclassified subsequently to profit or loss	-2,683,594.98	-50,170.88
(1) Changes arising from remeasurement of defined benefit plan	—	—
(2) Other comprehensive income using the equity method that will not be reclassified to profit or loss	—	—
(3) Change in the fair value of other equity instrument investments	-2,683,594.98	-50,170.88
(4) Change in fair value of credit risk of the Company	—	—
2. Other comprehensive income reclassified subsequently to profit or loss	-174,564,068.16	219,255,126.03
(1) Other comprehensive income using the equity method that will be reclassified to profit or loss	-13,673,306.83	-74,114,634.97
(2) Changes in fair value of other debt investments	—	—
(3) Amount of financial assets reclassified into other comprehensive income	—	—
(4) Credit impairment provisions for other debt investments	—	—
(5) Reserves for cash flow hedges	—	—
(6) Exchange difference on translation of financial statement in foreign currency	-160,890,761.33	293,369,761.00
(7) Others	—	—
(II) Other comprehensive income attributable to non-controlling interests, net of tax	-36,679,636.17	163,842,262.42
VII. Total comprehensive income	2,304,590,338.15	3,036,856,754.24
(I) Total comprehensive income attributable to the owners of the parent company	1,833,394,697.38	2,502,270,885.78
(II) Total comprehensive income attributable to non-controlling interests	471,195,640.77	534,585,868.46
VIII. Earnings per share:		
(I) Basic earnings per share (yuan/share)	0.75	0.86
(II) Diluted earnings per share (yuan/share)	0.75	0.85

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Chen Zhanyu

*Director of
the Accounting Department:*
Yan Jia

Consolidated Statement of Cash Flow

January — September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2024 (Jan–Sep)	First three quarters of 2023 (Jan–Sep)
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	30,140,941,020.19	31,291,201,615.51
Refund of taxes and levies	396,176,187.19	282,616,022.96
Other cash received relating to operating activities	1,014,810,121.01	1,862,007,814.60
Sub-total of cash inflow generated from operating activities	31,551,927,328.39	33,435,825,453.07
Cash paid for purchasing goods and receiving services	11,113,466,213.16	12,960,139,678.42
Cash paid to and on behalf of employees	8,472,222,959.74	8,032,804,716.41
Cash paid for all types of taxes	1,845,379,714.80	2,066,345,801.66
Other cash paid relating to operating activities	7,134,221,085.52	7,914,894,769.94
Sub-total of cash outflow generated from operating activities	28,565,289,973.22	30,974,184,966.43
Net cash flow generated from operating activities	2,986,637,355.17	2,461,640,486.64
II. Cash flow generated from investing activities:		
Cash received from disposal of investments	334,148,666.40	971,683,442.14
Cash received from returns on investments	1,019,256,256.61	888,386,091.11
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	238,760,527.63	7,183,164.91
Net cash received from disposal of subsidiaries and other operating segments	138,522,994.25	—
Other cash received relating to investing activities	93,073,923.23	1,260,013,178.06
Sub-total of cash inflow generated from investing activities	1,823,762,368.12	3,127,265,876.22
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	3,026,949,825.29	4,217,498,536.44
Cash paid for investments	931,718,461.75	691,319,201.85
Net cash paid for acquisition of subsidiaries and other operating segments	—	1,145,321,504.56
Other cash paid relating to investing activities	304,806,549.95	357,419,663.99
Sub-total of cash outflow generated from investing activities	4,263,474,836.99	6,411,558,906.84
Net cash flow generated from investing activities	-2,439,712,468.87	-3,284,293,030.62

Consolidated Statement of Cash Flow (*Continued*)

January — September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2024 (Jan-Sep)	First three quarters of 2023 (Jan-Sep)
III. Cash flow generated from financing activities:		
Cash received from capital contribution	168,075,471.89	43,943,339.47
Including: Cash received by subsidiaries from investments of non-controlling interests	168,075,471.89	43,943,339.47
Cash received from borrowings	21,739,468,572.59	18,051,361,530.05
Other cash received relating to financing activities	2,057,595,013.83	341,238,916.65
Sub-total of cash inflow generated from financing activities	23,965,139,058.31	18,436,543,786.17
Cash paid for debts settlement	21,800,975,343.77	15,547,919,509.95
Cash paid for the distribution of dividends, profits or interests	2,053,832,098.21	2,281,793,707.17
Including: Dividends and profits paid by subsidiaries to non-controlling interests	354,336,577.14	188,537,457.63
Other cash paid relating to financing activities	612,621,029.02	1,003,410,173.53
Sub-total of cash outflow generated from financing activities	24,467,428,471.00	18,833,123,390.65
Net cash flow generated from financing activities	-502,289,412.69	-396,579,604.48
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-69,635,970.14	131,327,968.77
V. Net increase of cash and cash equivalents	-25,000,496.53	-1,087,904,179.69
Plus: Opening balance of cash and cash equivalents	9,502,388,906.04	11,170,066,988.55
VI. Closing balance of cash and cash equivalents	9,477,388,409.51	10,082,162,808.86

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Chen Zhanyu

*Director of
the Accounting Department:*
Yan Jia

Balance Sheet of the Parent Company
30 September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2024	31 December 2023
Current assets:		
Cash and bank balances	1,797,938,351.88	1,988,658,295.70
Financial assets held for trading	127,031,312.53	117,694,923.39
Bills receivable	100,000,000.00	—
Other receivables	2,726,646,282.67	3,171,648,647.50
Including: Interests receivable	—	—
Dividends receivable	1,164,472,116.97	1,014,750,826.36
Non-current assets due within one year	2,588,685,263.01	2,791,425,788.28
Other current assets	917,163,708.07	867,012,556.85
Total current assets	8,257,464,918.16	8,936,440,211.72
Non-current assets:		
Long-term equity investments	37,995,020,489.48	34,784,570,722.60
Other non-current financial assets	35,697,488.67	39,372,380.23
Fixed assets	5,528,821.16	6,944,749.37
Intangible assets	1,199,975.34	1,345,791.33
Other non-current assets	3,591,334,262.06	4,772,993,094.64
Total non-current assets	41,628,781,036.71	39,605,226,738.17
Total assets	49,886,245,954.87	48,541,666,949.89
Current liabilities:		
Short-term loans	7,597,609,938.32	4,767,388,450.92
Wages payable	130,778,662.80	140,901,848.01
Tax payable	34,635,217.71	28,058,873.43
Other payables	2,855,614,862.21	2,635,838,431.07
Non-current liabilities due within one year	1,605,883,947.48	2,802,338,364.44
Other current liabilities	155,357,667.62	165,877,464.98
Total current liabilities	12,379,880,296.14	10,540,403,432.85
Non-current liabilities:		
Long-term loans	661,400,000.00	1,728,935,947.50
Bonds payable	240,000,000.00	—
Deferred tax liabilities	1,151,018,873.79	1,151,018,873.79
Total non-current liabilities	2,052,418,873.79	2,879,954,821.29
Total liabilities	14,432,299,169.93	13,420,358,254.14

Balance Sheet of the Parent Company (*Continued*)

30 September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2024	31 December 2023
Owners' Equity (or shareholders' equity):		
Share capital	2,671,326,465.00	2,672,398,711.00
Capital reserve	18,722,668,798.37	18,745,360,509.37
Less: Treasury shares	206,895,300.74	41,928,227.94
Other comprehensive income	-367,510,802.15	-366,187,879.22
Surplus reserve	1,336,199,355.50	1,336,199,355.50
Unappropriated profit	13,298,158,268.96	12,775,466,227.04
Total owners' equity (or shareholders' equity)	35,453,946,784.94	35,121,308,695.75
Total liabilities and owners' equity (or shareholders' equity)	49,886,245,954.87	48,541,666,949.89

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Chen Zhanyu

*Director of
the Accounting Department:*
Yan Jia

Income Statement of the Parent Company

January — September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2024 (Jan-Sep)	First three quarters of 2023 (Jan-Sep)
I. Operating revenue	35,782,951.79	1,893,196.41
Less: Tax and surcharges	7,274.51	83,196.47
General and administrative expenses	164,636,279.31	254,212,206.72
Research and development expenses	11,274,306.32	46,478,359.67
Finance costs	212,096,855.52	427,664,444.80
Including: Interest expenses	281,180,488.61	443,842,752.93
Interest income	75,874,478.95	32,349,634.56
Plus: Investment income (“-” indicating loss)	1,589,749,377.47	1,787,261,438.40
Including: Investment income from associates and joint ventures	1,411,193,740.37	1,603,943,770.23
Gains from changes in fair value (“-” indicating loss)	5,661,497.58	-49,175,569.96
Gains from disposal of assets (“-” indicating loss)	—	33,032.62
II. Operating profit (“-” indicating loss)	1,243,179,111.18	1,011,573,889.81
Plus: Non-operating revenue	—	—
Less: Non-operating expenses	1,551,000.00	1,927,900.00
III. Total profit (“-” indicating total loss)	1,241,628,111.18	1,009,645,989.81
Less: Income tax expenses	-2,897,465.40	376,863.73
IV. Net profit (“-” indicating net loss)	1,244,525,576.58	1,009,269,126.08
(I) Net profit from continuing operation (“-” indicating net loss)	1,244,525,576.58	1,009,269,126.08
(II) Net profit from discontinued operation (“-” indicating net loss)	—	—
V. Other comprehensive income, net of tax	-1,322,922.93	-65,487,521.89
(I) Other comprehensive income not reclassified subsequently to profit or loss	—	—
1. Changes arising from remeasurement of defined benefit plan	—	—
2. Other comprehensive income using the equity method that will not be reclassified to profit or loss	—	—
3. Change in the fair value of other equity instrument investments	—	—
4. Change in fair value of credit risk of the Company	—	—
(II) Other comprehensive income reclassified subsequently to profit or loss	-1,322,922.93	-65,487,521.89
1. Other comprehensive income using the equity method that will be reclassified to profit or loss	-1,322,922.93	-65,487,521.89
2. Change in the fair value of other debt investments	—	—
3. Amount of financial assets reclassified into other comprehensive income	—	—
4. Credit impairment provisions for other debt investments	—	—
5. Reserves for cash flow hedge	—	—
6. Exchange differences on translation of foreign currency financial statements	—	—
7. Others	—	—

Income Statement of the Parent Company (*Continued*)

January — September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2024 (Jan-Sep)	First three quarters of 2023 (Jan-Sep)
VI. Total comprehensive income	1,243,202,653.65	943,781,604.19
VII. Earnings per share:		
(I) Basic earnings per share (yuan/share)	NA	NA
(II) Diluted earnings per share (yuan/share)	NA	NA

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Chen Zhanyu

*Director of
the Accounting Department:*
Yan Jia

Statement of Cash Flow of the Parent Company

January — September 2024

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2024 (Jan-Sep)	First three quarters of 2023 (Jan-Sep)
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	37,632,346.76	11,767,989.89
Refund of taxes and levies	4,584,546.08	—
Other cash received relating to operating activities	42,325,756.10	594,239,036.32
Sub-total of cash inflow generated from operating activities	84,542,648.94	606,007,026.21
Cash paid to and on behalf of employees	114,646,858.73	167,453,866.63
Cash paid for all types of taxes	70,929.88	395,550.95
Other cash paid relating to operating activities	269,870,830.34	135,284,810.50
Sub-total of cash outflow generated from operating activities	384,588,618.95	303,134,228.08
Net cash flow generated from operating activities	-300,045,970.01	302,872,798.13
II. Cash flow generated from investing activities:		
Cash receipts from disposal of investments	—	127,390,820.47
Cash received from returns on investments	764,401,289.17	868,485,501.55
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	3,330.00	74,590.00
Sub-total of cash inflow generated from investing activities	764,404,619.17	995,950,912.02
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	—	2,198,968.76
Cash paid for investments	1,037,081,731.82	606,232,828.00
Sub-total of cash outflow generated from investing activities	1,037,081,731.82	608,431,796.76
Net cash flow generated from investing activities	-272,677,112.65	387,519,115.26
III. Cash flow generated from financing activities:		
Cash receipts from receiving investments	—	7,911,364.00
Cash received from borrowings	7,805,313,098.35	6,020,678,907.04
Other cash received relating to financing activities	9,205,122,013.42	11,574,289,643.93
Sub-total of cash inflow generated from financing activities	17,010,435,111.77	17,602,879,914.97
Cash paid for debts settlement	7,090,204,155.15	6,923,077,581.92
Cash paid for the distribution of dividends, profits or interest	1,014,200,301.97	1,478,712,730.80
Other cash paid relating to financing activities	8,703,795,215.72	9,762,454,493.12
Sub-total of cash outflow generated from financing activities	16,808,199,672.84	18,164,244,805.84
Net cash flow generated from financing activities	202,235,438.93	-561,364,890.87
IV. Effects of exchange rate fluctuations on cash and cash equivalents	67,699.91	411,909.24
V. Net increase of cash and cash equivalents	-370,419,943.82	129,438,931.76
Plus: Opening balance of cash and cash equivalents	985,958,295.70	722,772,306.06
VI. Closing balance of cash and cash equivalents	615,538,351.88	852,211,237.82

*Person in charge of
the Company:*
Wu Yifang

Chief Financial Officer:
Chen Zhanyu

*Director of
the Accounting Department:*
Yan Jia

(III) Status in relation to adjustments to the first implementation of financial statements at the beginning of the year for the implementation of new accounting standards or standard interpretations for the first time from 2024

Not applicable

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the People's Republic of China
29 October 2024

* *for identification purposes only*